NASDAQ:IDXG

Interpace Biosciences - IDXG Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.

Add

Compare

Today's Range: $2.39
▼
$2.60
50-Day Range: $4.75
▼
$10.40
52-Week Range: $2.57
▼
$10.42

Volume: 1,802 shs
Average Volume: 3,285 shs
Market Capitalization: $10.55 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About Interpace Biosciences (NASDAQ:IDXG) Stock

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.

Receive IDXG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Interpace Biosciences and its competitors with MarketBeat's FREE daily newsletter.

IDXG Stock News Headlines

June 2, 2022 | seekingalpha.com

PDI: 11.8% Yield, Diversified, Marginal Net Asset Premium

May 27, 2022 | seekingalpha.com

PDI Living Off Its Past Success

May 17, 2022 | seekingalpha.com

Interpace Biosciences GAAP EPS of -$0.53, revenue of $10.38M

May 9, 2022 | uk.finance.yahoo.com

Interpace Diagnostics Group, Inc. (IDXG)

March 31, 2022 | finance.yahoo.com

Interpace Biosciences Announces Full Year and Fourth Quarter 2021 Financial and Business Results

March 22, 2022 | seekingalpha.com

PDI: Stomaching Short Term Pain For Long Term Gain

February 22, 2022 | finance.yahoo.com

Interpace Biosciences Announces Update of Previously Announced CMS Billing Policy Impacting its Thyroid Tests

January 28, 2022 | finance.yahoo.com

Interpace Biosciences Terminates Rights Offering Announces Change in CMS Medicare Reimbursement of its Thyroid Tests

January 27, 2022 | finance.yahoo.com

Interpace Biosciences Announces Appointment of Vijay Aggarwal, Ph.D. as New Director

January 19, 2022 | seekingalpha.com

PIMCO Taxable CEF Update: PDI Values Up, Better Deals Available

January 12, 2022 | seekingalpha.com

Interpace Biosciences begins $30M rights offering

January 12, 2022 | finance.yahoo.com

Interpace Biosciences Announces Commencement of Fully Back-Stopped $30 Million Rights Offering

January 3, 2022 | finance.yahoo.com

Interpace Biosciences Announces Record Date for Proposed Fully Back-Stopped $30 Million Rights Offering

December 31, 2021 | seekingalpha.com

PDI: 100 Big-Dividend CEFs, REITs, MLPs, BDCs - These 4 Are Worth Considering

December 15, 2021 | seekingalpha.com

PDI: A Fresh Look Following The Merger

November 10, 2021 | finance.yahoo.com

Interpace Biosciences Announces Third Quarter 2021 Financial and Business Results

November 2, 2021 | finance.yahoo.com

Interpace Biosciences Announces New $8 Million Term Loan with BroadOak Capital Partners and Repayment of Private Equity Loans

October 28, 2021 | finance.yahoo.com

Interpace Biosciences Announces U.S. PTO Issuance of Patent No. 11,143,657 Titled: Topographic Genotyping for Determining the Diagnosis, Malignant Potential, and Biologic Behavior of Pancreatic Cysts and Related Conditions

October 21, 2021 | finance.yahoo.com

Interpace Diagnostics Announces US Patent Approval for Patent Application No. 11,118, 231 B2 Titled: microRNAs as Biomarkers for Distinguishing Benign from Malignant Thyroid Neoplasms

October 15, 2021 | finance.yahoo.com

Interpace Biosciences Announces New $7.5 Million Credit Facility with Comerica Bank

August 11, 2021 | finance.yahoo.com

Interpace Biosciences, Inc. (IDXG) Reports Q2 Loss, Tops Revenue Estimates

August 10, 2021 | finance.yahoo.com

Interpace Biosciences Announces Second Quarter 2021 Financial and Business Results

July 22, 2021 | bitcoinmagazine.com

Carbon Neutral Hosting Provider To List On Nasdaq Through Merger

July 14, 2021 | nasdaq.com

Interpace Biosciences Inc. (IDXG)

July 1, 2021 | finance.yahoo.com

Interpace Biosciences, Inc. (IDXG) Is a Great Choice for "Trend" Investors, Here's Why

See More Headlines

Receive IDXG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Interpace Biosciences and its competitors with MarketBeat's FREE daily newsletter.

IDXG Company Calendar

Last Earnings: 11/10/2021
Today: 8/15/2022
Next Earnings (Estimated): 11/08/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical & medical instruments
Sub-Industry: Health Care Services
Sector: Medical
Current Symbol: NASDAQ:IDXG
CUSIP: 69329V10
CIK: 1054102
Web: www.interpace.com
Phone: 855-776-6419
Fax: 862-207-7820
Employees: 152
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-14,940,000.00
Net Margins: -31.02%
Pretax Margin: -32.13%
Return on Equity: N/A
Return on Assets: -31.91%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.78
Quick Ratio: 0.78

Sales & Book Value

Annual Sales: $41.31 million
Price / Sales: 0.26
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($10.16) per share
Price / Book: -0.25

Miscellaneous

Outstanding Shares: 4,230,000
Free Float: 1,971,000
Market Cap: $10.55 million
Optionable: Not Optionable
Beta: 1.01

Key Executives

Dr. Thomas W. Burnell Ph.D. (Age 58)
Pres, CEO & Director
Comp: $425k
Mr. Thomas John Freeburg Ph.D. (Age 52)
Chief Accounting Officer, CFO, Treasurer & Sec.
Dr. Sydney D. Finkelstein
Chief Scientific Officer
Dr. Alidad Mireskandari M.B.A.
Ph.D., Chief Devel. Officer
Mr. Patrick Kane
VP & Corp. Controller

Key Competitors

View All Competitors

IDXG Stock - Frequently Asked Questions

Should I buy or sell Interpace Biosciences stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Interpace Biosciences in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" IDXG shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IDXG, but not buy additional shares or sell existing shares.
View IDXG analyst ratings or view top-rated stocks.
When is Interpace Biosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our IDXG earnings forecast.
How were Interpace Biosciences' earnings last quarter?: Interpace Biosciences, Inc. (NASDAQ:IDXG) issued its earnings results on Wednesday, November, 10th. The business services provider reported ($0.84) EPS for the quarter, missing the consensus estimate of ($0.62) by $0.22. The business services provider earned $9.47 million during the quarter, compared to analyst estimates of $11.50 million.
What other stocks do shareholders of Interpace Biosciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Interpace Biosciences investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), Histogenics (HSGX), Johnson & Johnson (JNJ), SCYNEXIS (SCYX), Cisco Systems (CSCO), Trevena (TRVN) and TherapeuticsMD (TXMD).

What is Interpace Biosciences' stock symbol?: Interpace Biosciences trades on the NASDAQ under the ticker symbol "IDXG."
What is Interpace Biosciences' stock price today?: One share of IDXG stock can currently be purchased for approximately $2.44.
How much money does Interpace Biosciences make?: Interpace Biosciences (NASDAQ:IDXG) has a market capitalization of $10.32 million and generates $41.31 million in revenue each year.
How many employees does Interpace Biosciences have?: The company employs 152 workers across the globe.
How can I contact Interpace Biosciences?: Interpace Biosciences' mailing address is MORRIS CORPORATE CENTER 1 BUILDING C 300 INTERPACE PARKWAY, PARSIPPANY NJ, 07054. The official website for the company is www.interpace.com. The business services provider can be reached via phone at 855-776-6419, via email at jgreen@edisongroup.com, or via fax at 862-207-7820.

This page (NASDAQ:IDXG) was last updated on 8/15/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Interpace Biosciences - IDXG Stock Forecast, Price & News

About Interpace Biosciences (NASDAQ:IDXG) Stock

IDXG Stock News Headlines

IDXG Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

IDXG Stock - Frequently Asked Questions

MarketBeat Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources